Here, targeting CXCR4 by CRISPR/Cas9 in HCC cells can inhibit invasion, proliferation and migration, reverse EMT, increase chemosensitivity and decrease the malignancy of HCC in vitro and in vivo (Wang X. et al., 2017). This evidence concerns the gene CXCR4 and hepatocellular carcinoma.